-
Unite as one, all the people fight against the epidemic
Time of Update: 2021-09-10
In the spring of 18 years ago, in the face of the sudden impact of the SARS epidemic, the Party Central Committee calmly responded to and gave instructions, putting the people’s health and life safety first, and in the difficult and complicated situation, it focused on prevention and control work with the other.
-
Dirui Medical's 2 product medical device registration certificate changes
Time of Update: 2021-09-06
Vaginal secretion analysis test strip (dry chemical method)Change the applicable model to: Applicable to Dirui: automatic gynecological secretion analysis system (model: GMD-S600); vaginal secretion detector (model: GD-S120) .
-
Express delivery of siRNA + neutralizing antibody therapy, Vir hepatitis B combination therapy completed the first case of phase 2 trial administration
Time of Update: 2021-08-08
▲The modification of the Fc-terminus of the neutralizing antibody gives VIR-3434 the potential to become a therapeutic vaccine (picture source: reference [4]) This multi-center, open-label phase 2 trial aims to evaluate about 90 patients receiving nucleosides In patients with chronic hepatitis B (18-65 years old) treated with reverse transcriptase inhibitors, the safety, tolerability and efficacy of the combined treatment of VIR-2218 and VIR-3434 .
-
Countdown to 100 days Thermo Fisher has participated in CIIE for four consecutive times
Time of Update: 2021-07-31
The world leader in the field of science, Thermo Fisher Scientific (hereinafter referred to as "Thermo "Fly") will appear at the CIIE for the fourth consecutive year, fully demonstrating the company's innovative products and solutions in vertical fields such as pharmaceuticals and biopharmaceuticals, medical health, academic research and application markets .
-
Professor Xie Rong, a famous anesthesiologist and medical educator in my country, dies
Time of Update: 2021-06-10
Members of the committee members A farewell ceremony for the body of Professor Xie Rong is scheduled to be held at the funeral home of Peking University First Hospital at 7:00 am on June 7, 2021 (Monday).
-
Chinese scholars discovered gastric cancer anti-tumor immune "super soldier" cells
Time of Update: 2021-06-01
(Finish) Medical Network, May 27, after 3 years of research, Chinese medical experts have discovered and verified the "super soldier" against tumor cells in the gastric cancer microenvironment, providing a new model for the improvement of the prognosis prediction model of gastric cancer patients and the individualized choice of immunotherapy.
-
There are too many causes of "digestive tract bleeding", can't remember
Time of Update: 2021-05-22
Although endoscopy is the preferred method for locating and qualitative diagnosis of gastrointestinal bleeding, its diagnosis accuracy rate is 80%~94%, which can solve 90% of the etiological diagnosis of gastrointestinal bleeding, but in the basic level lacking endoscopic conditions It is also important for medical institutions to judge the cause of bleeding through clinical manifestations and other auxiliary examinations.
-
3 NEJM articles on the same day: Post-vaccination infection is a case, and the new crown vaccine is generally effective for medical staff
Time of Update: 2021-04-27
The first study from the University of California, San Diego (UCSD) and University of California, Los Angeles (UCLA) teams analyzed a total of 36,659 medical staff in their medical systems as of February 9th that were vaccinated with Pfizer/BNT162b2 Or the effect of Moderna's new crown vaccine, of which 28,184 people (77%) have already received the second dose of vaccine.
-
Express | Significantly improve the overall survival of bladder cancer patients, "first-in-class" antibody-conjugated drug Phase 3 clinical results released
Time of Update: 2021-03-25
▎The content team editor of WuXi AppTec recently, Seagen (formerly Seattle Genetics) and Astellas Pharma jointly announced an innovative antibody conjugate drug Padcev (enfortumab vedotin-ejfv) to treat locally advanced or metastatic urothelial cancer The patient's Phase 3 clinical trial results were published in the New England Journal of Medicine (NEJM).
-
Your concerns about the new coronavirus vaccination are all here
Time of Update: 2021-01-22
Zheng Zhongwei, head of the special working group on vaccine research and development of the joint prevention and control mechanism and director of the National Health and Wellness Commission's Medical and Health Science and Technology Development Research Center, said: At present, the cumulative number of infections worldwide has exceeded 90 million, and we have not yet seen an inflection point in the whole epidemic.
-
Monitoring report authoritative release! How's the drG paid for by piloting more than half
Time of Update: 2021-01-19
Wen | China's medical insurance dream continues to promote the reform of medical insurance payment methods, explore the fine management model, which is the core of improving the payment mechanism of
-
186 drugs not sold in hospitals (with list
Time of Update: 2020-11-04
Medicine Network November 2nd, with the implementation of a batch of national collection, the minimum price reduction requirements for unseeded drugs are constantly refreshed, there will be a large nu
-
Derazantinib Treatment of Advanced Gastric Cancer: Upcoming Phase I/II Study
Time of Update: 2020-10-11
the multi-queue study was designed to assess the effectiveness and safety of deazantinib's treatment of patients with advanced stomach cancer with FGFR gene abnormalities.
patients with advanced stomach cancer with FGFR genetic abnormalities have very poor prognostics and their medical needs are far from being met." .
-
Lepu Medical's half-year profit fell significant business adjustment
Time of Update: 2020-08-05
the reporting period, the non-recurring profit and loss is expected to affect the company's net profit attributable to shareholders of listed companies by about 20 million yuan, mainly due to the shanghai Junshi Biopharmaceutical Technology Co., Ltd. related income of 235.8108 million yuan.
-
FDA COVID-19 Clinical Trial Guide: Welcome to Diverse Phase 2, Phase 3 Trial Designs
Time of Update: 2020-07-09
One of the outstanding features of the COVID-19 pipeline is diversity, which covers a wide range of drug action mechanisms Under the premise of adhering to adequate safety evaluation, the phase 2 and
